UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
____________________
____________________
FORM 8-K
_____________________
_____________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 11, 2020
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
(Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (866 ) 871-8519
NOT APPLICABLE
(Former Name or Former Address, if Changed Since Last Report)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b)) | |
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company | |
☐ | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. |
Section 2—Financial Information
Item 2.02. | Results of Operations and Financial Condition. |
On Monday, May 11, 2020, AMN Healthcare Services, Inc. (the “Company”) reported its first quarter 2020 results for the financial period ended March 31, 2020. The Company’s first quarter 2020 results are discussed in detail in the press release ("Press Release"), which is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The first quarter 2020 results disclosed in the Press Release presented the Company's first quarter 2020 results in accordance with its new segment reporting structure.
In connection with the new segment reporting structure, the Company is furnishing a summary of the Company's historical segment results recast for the new reporting structure. Exhibit 99.2 contains unaudited supplemental segment financial and operating data for the years ended December 31, 2019, 2018 and 2017 reflecting this realignment. This information is also available on the Company's website at http://amnhealthcare.investorroom.com.
The information contained in Exhibit 99.2 is being furnished in order to provide the financial community with historical financial information that is presented on a basis consistent with the new reporting structure and does nto represent a restatement of previously issued financial statements.
The information in this Item 2.02 and Exhibit 99.1 and Exhibit 99.2 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent as shall be expressly set forth by specific reference in such filing.
Item 9.01. | Financial Statements and Exhibits. | |
(d) Exhibits.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AMN Healthcare Services, Inc. | |
Date: May 11, 2020 | By: | /s/ Susan R. Salka |
Susan R. Salka | ||
President & Chief Executive Officer | ||
AMN HEALTHCARE ANNOUNCES FIRST QUARTER 2020 RESULTS
Quarterly revenue of $602 million;
GAAP EPS of $0.27 and adjusted EPS of $0.79
DALLAS & SAN DIEGO – (May 11, 2020) – AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its first quarter 2020 financial results. Financial highlights are as follows:
Dollars in millions, except per share amounts.
Q1 2020 | % Change Q1 2019 | |
Revenue | $602.5 | 13% |
Gross profit | $202.1 | 14% |
Net income | $13.0 | (62)% |
Diluted EPS | $0.27 | (62)% |
Adjusted diluted EPS* | $0.79 | 5% |
Adjusted EBITDA* | $74.0 | 12% |
* See “Non-GAAP Measures” below for a discussion of our use of non-GAAP items and the table entitled “Non-GAAP Reconciliation Tables” for a reconciliation of non-GAAP items.
Business Highlights
• | First quarter financial results in line with guidance, with favorable trends and strong momentum across most business lines in the first two months of the year. |
• | Revenue of $602 million was 13% above prior year, with organic revenue higher by 3%, and adjusted EBITDA was $74 million. |
• | With the nationwide reduction in elective procedures and overall healthcare utilization starting in the second half of March due to COVID-19, all divisions except Travel Nurse and VMS were negatively impacted in the first quarter. |
• | Stratus Video, the remote video interpretation business acquired in mid-February, contributed $14 million of revenue in the first quarter, just below expectations due to COVID-19. |
• | We have realigned our three reportable segments to better correlate with our business operations and organizational structure. |
1
“I am immensely proud of the incredible AMN team, our clients, our industry and most importantly, our front-line healthcare professionals for the way they have risen to the challenge of this global pandemic,” said Susan R. Salka, Chief Executive Officer of AMN Healthcare. “In March and April, we mobilized thousands of healthcare professionals to respond to the needs of our clients and the patients and communities they serve. To handle this dramatic COVID-19 demand surge, our teams rallied with hundreds of team members shifting into new roles to support our clients and healthcare professionals.
“Under pressure from the pandemic and the urgent patient care needs across the country, we were quickly able to deploy several new, innovative solutions,” Ms. Salka added. “In April we expanded our scalable VMS solution, Open Talent Marketplace, allowing a multitude of healthcare facilities to quickly staff and manage their entire range of contingent talent. We saw a significant increase in utilization of our emerging Televate teletherapy platform by the school districts we serve. We added new functionality to our Stratus platform that enabled clients to utilize it for broader telehealth care. AMN launched a new telehealth platform, AMN Cares, for care teams to interact with patients or employees at home. We also accelerated the release of AMN Passport, the most comprehensive mobile app for healthcare professionals in the industry.”
“As needs related to COVID-19 support decelerated in late April and healthcare utilization remained low across the country, demand for most of our service lines also declined. As a result, we have made adjustments to our cost structure to reflect this market environment. At the same time, we remain focused on our total talent strategy to ensure we emerge as an even stronger and more agile organization,” Ms. Salka said.
First Quarter 2020 Results
2
Consolidated revenue for the quarter was $602 million, a 13% increase over prior year and 3% higher than prior quarter. On an organic basis, consolidated revenue was up 3% over prior year. Beginning this quarter, we are reporting with three realigned business segments. The Nurse and Allied Solutions segment now includes our revenue cycle solutions business. Physician and Leadership Solutions is a new segment that encompasses contingent and permanent leadership solutions, locum tenens, and physician permanent placement. Technology and Workforce Solutions, the third segment, includes remote video interpreting, vendor management solutions, predictive analytics, RPO and credentialing services.
Revenue for the Nurse and Allied Solutions segment was $424 million up 14% year over year (3% organic) and flat sequentially. Travel Nurse division revenue grew 12% year over year with 6% organic growth. Allied division revenue increased 41% year over year, 5% organic.
The Physician and Leadership Solutions segment reported revenue of $138 million, up 1% year over year and down 1% sequentially. Technology and Workforce Solutions segment revenue was $40 million for an increase of 84% year over year (13% organic), driven in large part by our recent acquisitions of b4health and Stratus Video.
Gross margin was 33.5%, higher by 30 basis points year over year and lower by 10 basis points sequentially. The year-over-year variance was driven primarily by a favorable segment mix shift.
SG&A expenses were $146 million, or 24.3% of revenue, compared with $120 million, or 22.5% of revenue, in the same quarter last year. SG&A was $133 million, or 22.7% of revenue, in the previous quarter. The year-over-year increase in SG&A costs included a $7 million increase in one-time costs related to recent acquisitions, as well as $9 million of SG&A from the acquired companies. The remainder of the SG&A increase from prior year was due mainly to higher employee-related expenses and an increase in bad debt reserves due largely to the COVID-19 crisis.
3
Income from operations was $36 million, or 5.9% of revenue, compared with $45 million, or 8.5% of revenue, in the same quarter last year. Adjusted EBITDA was $74 million, a year-over-year increase of 12%. Adjusted EBITDA margin was 12.3%, representing a decrease of 10 basis points year over year.
Net income was $13 million, or $0.27 per diluted share, compared with $34 million, or $0.71 per diluted share, in the same quarter last year. Adjusted diluted EPS was $0.79.
At March 31, 2020, cash and cash equivalents totaled $98 million. Cash flow from operations was $51 million for the quarter, and capital expenditures were $14 million. The Company ended the quarter with total debt outstanding of $1,100 million with a leverage ratio of 3.1 to 1. Subsequent to quarter end, the Company reduced total debt outstanding to $1,050 million and currently has more than $200 million available to draw under the revolving credit facility.
4
Second Quarter 2020 Outlook
The stay-at-home orders and suspension of elective procedures have caused a material decrease in healthcare utilization and delayed buying decisions from our clients. Travel nurse demand was remarkably strong in the second half of March and much of April. However, recent demand has fallen significantly, reflecting the decline in crisis assignments and healthcare utilization. Overall, for the second quarter, we expect Nurse and Allied Solutions segment revenue to be above prior year by 7-10%, with higher travel nurse revenue partly offset by lower revenue cycle solutions and labor disruption revenue. For this segment, the trajectory of volume and revenue is declining through the quarter, and we expect volumes for nurse, allied and revenue cycle to be below prior year in June.
For our Physician and Leadership Solutions and Technology and Workforce Solutions segments, April revenue for most service lines was below prior-year levels by about 10-30%. Revenue has stabilized, and we expect demand to grow from current levels for these businesses as elective procedures resume and overall healthcare utilization increases.
Based on the above trends, we are projecting second quarter revenue to be in a range of $550 million to $570 million. This wide range reflects the uncertainty and volatility of business activity. In response to the lower level of revenue, we have taken several steps to reduce spending across the enterprise. These actions, plus the variable nature of certain expenses, have decreased our SG&A by approximately 15% on an annualized basis from our pre-COVID-19 run rate. Second quarter operating margin is expected to be above 6%, and adjusted EBITDA margin is expected to be above 12%.
Second quarter estimates for certain financial items include depreciation of $7.5 million, non-cash amortization expense of $15.6 million, interest expense of $10.7 million, integration expenses of $4-5 million, and an adjusted tax rate of 32%.
5
Conference Call on May 11, 2020
AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare, will host a conference call to discuss its first quarter 2020 financial results and outlook on Monday, May 11, 2020, at 5:00 p.m. Eastern Time. A live webcast of the call can be accessed through AMN Healthcare’s website at http://amnhealthcare.investorroom.com/eventcalendar. Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software. Interested parties may participate live via telephone by dialing (844) 721-7241 in the U.S. or (409) 207-6955 internationally and using participant code 4038932. Following the conclusion of the call, a replay of the webcast will be available at the Company’s website. Alternatively, a telephonic replay of the call will be available starting at 7:30 p.m. Eastern Time on May 11, 2020, and can be accessed until 11:59 p.m. Eastern Time on May 25, 2020, by calling (800) 207-1041 in the U.S. or (402) 970-0847 internationally, with access code 1880818.
About AMN Healthcare
AMN Healthcare is the leader and innovator in total talent solutions for healthcare organizations across the nation. The Company provides access to the most comprehensive network of quality healthcare professionals through its innovative recruitment strategies and breadth of career opportunities. With insights and expertise, AMN Healthcare helps providers optimize their workforce to successfully reduce complexity, increase efficiency and improve patient outcomes. AMN total talent solutions include managed services programs, clinical and interim healthcare leaders, temporary staffing, executive search solutions, vendor management systems, recruitment process outsourcing, predictive modeling, language interpretation services, revenue cycle solutions, credentialing, and other services. Clients include acute-care hospitals, community health centers and clinics, physician practice groups, retail and urgent care centers, home health facilities, schools and many other healthcare settings. AMN Healthcare is committed to fostering and maintaining a diverse team that reflects the communities we serve. Our commitment to the inclusion of many different backgrounds, experiences and perspectives enables our innovation and leadership in the healthcare services industry.
The Company’s common stock is listed on the New York Stock Exchange under the symbol “AMN.” For more information about AMN Healthcare, visit www.amnhealthcare.com, where the
6
Company posts news releases, investor presentations, webcasts, SEC filings and other material information. The Company also utilizes email alerts and Really Simple Syndication (“RSS”) as routine channels to supplement distribution of this information. To register for email alerts and RSS, visit http://amnhealthcare.investorroom.com/emailalerts.
Non-GAAP Measures
This earnings release contains certain non-GAAP financial information, which the Company provides as additional information, and not as an alternative, to the Company’s condensed consolidated financial statements presented in accordance with GAAP. These non-GAAP financial measures include (1) adjusted EBITDA, (2) adjusted EBITDA margin and (3) adjusted net income, and (4) adjusted diluted EPS. The Company provides such non-GAAP financial measures because management believes that they are useful both to management and investors as a supplement, and not as a substitute, when evaluating the Company’s operating performance. Additionally, management believes that adjusted EBITDA, adjusted EBITDA margin, adjusted net income, and
7
adjusted diluted EPS serve as industry-wide financial measures. The Company uses adjusted EBITDA for making financial decisions and allocating resources. The non-GAAP measures in this release are not in accordance with, or an alternative to, GAAP measures and may be different from non-GAAP measures, or may be calculated differently than other similarly titled non-GAAP measures, reported by other companies. They should not be used in isolation to evaluate the Company’s performance. A reconciliation of non-GAAP measures identified in this release, along with further detail about the use and limitations of certain of these non-GAAP measures, may be found below in the table entitled “Non-GAAP Reconciliation Tables” under the caption entitled “Reconciliation of Non-GAAP Items” and the footnotes thereto or on the Company’s website at http://amnhealthcare.investorroom.com/financialreports. Additionally, from time to time, additional information regarding non-GAAP financial measures, including pro forma measures, may be made available on the Company’s website.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among others, statements concerning future demand projections, projected healthcare utilization rates, projections regarding the trajectory of travel nurse volume and revenue, revenue projections for our Physician and Leadership Solutions and Technology and Workforce Solutions segments, the Company's projected annualized SG&A performance and our guidance for second quarter 2020 Nurse and Allied Solutions segment revenue, allied and revenue cycle solutions revenue, consolidated revenue, travel nurse revenue, operating margin, adjusted EBITDA margin, depreciation expense, non-cash amortization expense, interest expense, integration expenses, and adjusted tax rate. The Company bases these forward-looking statements on its current expectations, estimates and projections about future events and the industry in which it operates using information currently available to it. Actual results could differ materially from those discussed in, or implied by, these forward-looking statements. Forward-looking statements are identified by words such as “believe,” "project," “anticipate,” “expect,” “intend,” “plan,” “will,” “may,” “estimates,” variations of such words and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.
8
The Company’s ability to meet the targets and expectations noted in our second quarter 2020 outlook depends upon, among other factors, (i) the magnitude and duration of the effects of the COVID-19 pandemic on our business, financial condition and results of operations, (ii) the duration of the period that hospitals and other healthcare entities decrease their utilization of temporary employees, physicians, leaders and other workforce technology applications as a result of the suspension or restrictions placed on non-essential and elective healthcare as a result of the COVID-19 pandemic, (iii) the duration of the period that individuals may continue to forgo non-essential and elective healthcare once “safer at home” restrictions and recommendations are lifted, (iv) the extent and duration of the period that a significant spike in unemployment that has resulted from the COVID-19 pandemic will cause an increase in under- and uninsured patients and a corresponding reduction in overall healthcare utilization and demand for our services, (v) the extent to which the COVID-19 pandemic may disrupt our operations due to the unavailability of our employees or healthcare professionals due to illness, risk of illness, quarantines, travel restrictions or other factors that limit our existing or potential workforce and pool of candidates, (vi) the severity and duration of the impact the COVID-19 pandemic has on the financial condition and cash flow of many hospitals and healthcare systems such that it impairs their ability to make payments to us, timely or otherwise, for services rendered, (vii) our ability to anticipate and quickly respond to changing marketplace conditions, such as alternative modes of healthcare delivery, reimbursement, or client needs, (viii) our ability to manage the pricing impact that the COVID-19 pandemic and consolidation of healthcare delivery organizations may have on our business, (ix) our ability to develop and evolve our current technology offerings and capabilities and implement new infrastructure and technology systems to optimize our operating results and manage our business effectively, (x) our ability to comply with extensive and complex federal and state laws and regulations related to the conduct of our operations, costs and payment for services and payment for referrals as well as laws regarding employment practices, (xi) our ability to recruit and retain sufficient quality healthcare professionals at reasonable costs, and (xii) our ability to consummate and effectively incorporate acquisitions into our business.
For a discussion of additional risk factors and a more complete discussion of some of the cautionary statements noted above that could cause actual results to differ from those implied by the forward-looking statements contained in this press release, please refer to our most recent Annual Report on Form 10-K for the year ended December 31, 2019, our subsequent Quarterly
9
Reports on Form 10-Q and our Current Reports on Form 8-K. Be advised that developments subsequent to this press release are likely to cause these statements to become outdated and the Company is under no obligation (and expressly disclaims any such obligation) to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.
Contact:
Randle Reece
Director, Investor Relations
866.861.3229
10
AMN Healthcare Services, Inc.
Condensed Consolidated Statements of Comprehensive Income
(in thousands, except per share amounts)
(unaudited)
Three Months Ended | |||||||||||
March 31, | December 31, | ||||||||||
2020 | 2019 | 2019 | |||||||||
Revenue | $ | 602,461 | $ | 532,441 | $ | 586,892 | |||||
Cost of revenue | 400,395 | 355,682 | 389,759 | ||||||||
Gross profit | 202,066 | 176,759 | 197,133 | ||||||||
Gross margin | 33.5 | % | 33.2 | % | 33.6 | % | |||||
Operating expenses: | |||||||||||
Selling, general and administrative (SG&A) | 146,234 | 119,997 | 133,158 | ||||||||
SG&A as a % of revenue | 24.3 | % | 22.5 | % | 22.7 | % | |||||
Depreciation and amortization | 20,089 | 11,710 | 17,007 | ||||||||
Total operating expenses | 166,323 | 131,707 | 150,165 | ||||||||
Income from operations | 35,743 | 45,052 | 46,968 | ||||||||
Operating margin (1) | 5.9 | % | 8.5 | % | 8.0 | % | |||||
Interest expense, net, and other (2) | 11,054 | 5,673 | 8,859 | ||||||||
Income before income taxes | 24,689 | 39,379 | 38,109 | ||||||||
Income tax expense | 11,724 | 5,257 | 10,627 | ||||||||
Net income | $ | 12,965 | $ | 34,122 | $ | 27,482 | |||||
Net income as a % of revenue | 2.2 | % | 6.4 | % | 4.7 | % | |||||
Other comprehensive income (loss): | |||||||||||
Foreign currency translation and other | (47 | ) | (101 | ) | 59 | ||||||
Other comprehensive income (loss) | (47 | ) | (101 | ) | 59 | ||||||
Comprehensive income | $ | 12,918 | $ | 34,021 | $ | 27,541 | |||||
Net income per common share: | |||||||||||
Basic | $ | 0.27 | $ | 0.73 | $ | 0.59 | |||||
Diluted | $ | 0.27 | $ | 0.71 | $ | 0.58 | |||||
Weighted average common shares outstanding: | |||||||||||
Basic | 47,359 | 46,784 | 46,713 | ||||||||
Diluted | 47,641 | 47,772 | 47,573 | ||||||||
AMN Healthcare Services, Inc.
Non-GAAP Reconciliation Tables
(dollars in thousands, except per share data)
(unaudited)
Three Months Ended | |||||||||||
March 31, | December 31, | ||||||||||
2020 | 2019 | 2019 | |||||||||
Reconciliation of Non-GAAP Items: | |||||||||||
Net income | $ | 12,965 | $ | 34,122 | $ | 27,482 | |||||
Income tax expense | 11,724 | 5,257 | 10,627 | ||||||||
Income before income taxes | 24,689 | 39,379 | 38,109 | ||||||||
Interest expense, net, and other (2) | 11,054 | 5,673 | 8,859 | ||||||||
Income from operations | 35,743 | 45,052 | 46,968 | ||||||||
Depreciation and amortization | 20,089 | 11,710 | 17,007 | ||||||||
Depreciation (included in cost of revenue) (3) | 145 | — | — | ||||||||
Share-based compensation | 4,927 | 5,186 | 4,528 | ||||||||
Acquisition, integration, and other costs (4) | 13,077 | 4,029 | 6,936 | ||||||||
Adjusted EBITDA (5) | $ | 73,981 | $ | 65,977 | $ | 75,439 | |||||
Adjusted EBITDA margin (6) | 12.3 | % | 12.4 | % | 12.9 | % | |||||
Net income | $ | 12,965 | $ | 34,122 | $ | 27,482 | |||||
Adjustments: | |||||||||||
Amortization of intangible assets | 13,431 | 6,651 | 11,074 | ||||||||
Acquisition, integration, and other costs (4) | 13,077 | 4,029 | 6,936 | ||||||||
Equity instrument fair value changes (2) | 1,298 | — | — | ||||||||
Debt financing related costs | — | — | 594 | ||||||||
Tax effect on above adjustments | (7,230 | ) | (2,777 | ) | (4,838 | ) | |||||
Tax effect of COLI fair value changes (7) | 5,255 | (1,527 | ) | (1,002 | ) | ||||||
Excess tax deficiencies (benefits) related to equity awards (8) | (1,221 | ) | (4,569 | ) | 203 | ||||||
Adjusted net income (9) | 37,575 | 35,929 | 40,449 | ||||||||
GAAP diluted net income per share (EPS) | $ | 0.27 | $ | 0.71 | $ | 0.58 | |||||
Adjustments | 0.52 | 0.04 | 0.27 | ||||||||
Adjusted diluted EPS (10) | $ | 0.79 | $ | 0.75 | $ | 0.85 | |||||
AMN Healthcare Services, Inc.
Supplemental Segment Financial and Operating Data
(dollars in thousands, except operating data)
(unaudited)
Three Months Ended | |||||||||||
March 31, | December 31, | ||||||||||
2020 | 2019 | 2019 | |||||||||
Revenue | |||||||||||
Nurse and allied solutions | $ | 424,346 | $ | 373,472 | $ | 422,705 | |||||
Physician and leadership solutions | 137,842 | 137,077 | 139,394 | ||||||||
Technology and workforce solutions | 40,273 | 21,892 | 24,793 | ||||||||
$ | 602,461 | $ | 532,441 | $ | 586,892 | ||||||
Segment operating income (11) | |||||||||||
Nurse and allied solutions | $ | 59,608 | $ | 53,556 | $ | 61,021 | |||||
Physician and leadership solutions | 14,569 | 15,872 | 19,098 | ||||||||
Technology and workforce solutions | 15,295 | 10,383 | 10,754 | ||||||||
89,472 | 79,811 | 90,873 | |||||||||
Unallocated corporate overhead | 15,491 | 13,834 | 15,434 | ||||||||
Adjusted EBITDA (5) | $ | 73,981 | $ | 65,977 | $ | 75,439 | |||||
Gross Margin | |||||||||||
Nurse and allied solutions | 28.5 | % | 28.5 | % | 29.0 | % | |||||
Physician and leadership solutions | 36.7 | % | 36.6 | % | 37.2 | % | |||||
Technology and workforce solutions | 75.7 | % | 92.6 | % | 92.3 | % | |||||
Operating Data: | |||||||||||
Nurse and allied solutions | |||||||||||
Average healthcare professionals on assignment (12) | 11,411 | 10,447 | 11,246 | ||||||||
Physician and leadership solutions | |||||||||||
Days filled (13) | 40,284 | 40,496 | 40,149 | ||||||||
Revenue per day filled (14) | $ | 1,968 | $ | 1,988 | $ | 1,941 | |||||
AMN Healthcare Services, Inc.
Condensed Consolidated Balance Sheets
(dollars in thousands, except leverage ratio)
(unaudited)
March 31, 2020 | December 31, 2019 | March 31, 2019 | |||||||||
Assets | |||||||||||
Current assets: | |||||||||||
Cash and cash equivalents | $ | 97,509 | $ | 82,985 | $ | 19,116 | |||||
Accounts receivable, net | 376,528 | 352,685 | 365,231 | ||||||||
Accounts receivable, subcontractor | 75,938 | 72,714 | 55,607 | ||||||||
Prepaid and other current assets | 50,619 | 52,115 | 48,933 | ||||||||
Total current assets | 600,594 | 560,499 | 488,887 | ||||||||
Restricted cash, cash equivalents and investments | 60,873 | 62,170 | 61,279 | ||||||||
Fixed assets, net | 116,718 | 104,832 | 93,625 | ||||||||
Operating lease right-of-use assets | 87,217 | 89,866 | 97,055 | ||||||||
Other assets | 104,829 | 120,254 | 105,590 | ||||||||
Goodwill | 851,459 | 595,551 | 464,923 | ||||||||
Intangible assets, net | 638,443 | 398,474 | 326,466 | ||||||||
Total assets | $ | 2,460,133 | $ | 1,931,646 | $ | 1,637,825 | |||||
Liabilities and stockholders’ equity | |||||||||||
Current liabilities: | |||||||||||
Accounts payable and accrued expenses | $ | 175,188 | $ | 156,140 | 153,566 | ||||||
Accrued compensation and benefits | 153,018 | 170,932 | 135,792 | ||||||||
Current portion of notes payable | 6,250 | — | — | ||||||||
Current portion of operating lease liabilities | 14,634 | 13,943 | 12,341 | ||||||||
Deferred revenue | 12,587 | 11,788 | 11,459 | ||||||||
Other current liabilities | 11,383 | 25,302 | 20,112 | ||||||||
Total current liabilities | 373,060 | 378,105 | 333,270 | ||||||||
Revolving credit facility | 225,000 | — | 150,000 | ||||||||
Notes payable, less unamortized fees | 858,906 | 617,159 | 320,798 | ||||||||
Deferred income taxes, net | 104,262 | 46,618 | 20,079 | ||||||||
Operating lease liabilities | 88,090 | 91,209 | 99,946 | ||||||||
Other long-term liabilities | 61,735 | 61,813 | 63,746 | ||||||||
Total liabilities | 1,711,053 | 1,194,904 | 987,839 | ||||||||
Commitments and contingencies | |||||||||||
Stockholders’ equity: | 749,080 | 736,742 | 649,986 | ||||||||
Total liabilities and stockholders’ equity | $ | 2,460,133 | $ | 1,931,646 | $ | 1,637,825 | |||||
Leverage ratio (15) | 3.1 | 2.0 | 1.9 | ||||||||
AMN Healthcare Services, Inc.
Summary Condensed Consolidated Statements of Cash Flows
(dollars in thousands)
(unaudited)
Three Months Ended | |||||||||||
March 31, | December 31, | ||||||||||
2020 | 2019 | 2019 | |||||||||
Net cash provided by operating activities | $ | 51,365 | $ | 36,214 | $ | 78,657 | |||||
Net cash used in investing activities | (492,137 | ) | (36,248 | ) | (38,218 | ) | |||||
Net cash provided by financing activities | 456,126 | 1,790 | 159 | ||||||||
Effect of exchange rates on cash | (47 | ) | (101 | ) | 59 | ||||||
Net increase in cash, cash equivalents and restricted cash | 15,307 | 1,655 | 40,657 | ||||||||
Cash, cash equivalents and restricted cash at beginning of period | 153,962 | 84,324 | 113,305 | ||||||||
Cash, cash equivalents and restricted cash at end of period | $ | 169,269 | $ | 85,979 | $ | 153,962 | |||||
AMN Healthcare Services, Inc.
Additional Supplemental Non-GAAP Disclosure
Reconciling Operating Margin Guidance to
Adjusted EBITDA Margin Guidance
Adjusted EBITDA margin represents operating margin excluding the impact of (A) depreciation and amortization expense, (B) share-based compensation and (C) acquisition, integration, and other costs. Due to the impact that the COVID-19 pandemic has had on the healthcare industry and the resulting uncertainty the pandemic is having on our future financial performance, we are unable to provide a quantitative reconciliation of our projected second quarter 2020 adjusted EBITDA margin to our projected operating margin without undertaking unreasonable efforts.
(1) | Operating margin represents income from operations divided by revenue. |
(2) | Interest expense, net, and other for the three months ended March 31, 2020 includes $1,298,000 related to changes in the fair value of equity instruments. Since the changes in fair value is unrelated to the Company’s operating performance, we excluded the impact from the calculation of adjusted net income and adjusted diluted EPS for the three months ended March 31, 2020. |
(3) | A portion of depreciation expense for Stratus Video, which was acquired in February 2020, is included in cost of revenue for the three months ended March 31, 2020. Beginning in 2020, we exclude the impact of depreciation included in cost of revenue from the calculation of adjusted EBITDA. |
(4) | Acquisition, integration, and other costs for the three months ended March 31, 2020 include advisory fees contingent upon closing of the Stratus Video acquisition of $5,000,000. Acquisition, integration, and other costs of $4,029,000 for the three months ended March 31, 2019 included $2,100,000 of extraordinary legal expenses and a decrease in contingent consideration liabilities for recently acquired companies of $700,000. We exclude the impact of extraordinary legal expenses from the calculation of adjusted EBITDA because we believe that these expenses are not indicative of the Company’s operating performance. |
(5) | Adjusted EBITDA represents net income plus interest expense (net of interest income) and other, income tax expense, depreciation and amortization, depreciation (included in cost of revenue), acquisition, integration, and other costs, extraordinary legal expenses, and share-based compensation. Management believes that adjusted EBITDA provides an effective measure of the Company’s results, as it excludes certain items that management believes are not indicative of the Company’s operating performance and is a measure used in the Company’s credit agreement and the indentures governing our 5.125% Senior Notes due 2024 and our 4.625% Senior Notes due 2027. Adjusted EBITDA is not intended to represent cash flows for the period, nor has it been presented as an alternative to income from operations or net income as an indicator of operating performance. Although management believes that some of the items excluded from adjusted EBITDA are not indicative of the Company’s operating performance, these items do impact the statement of comprehensive income, and management therefore utilizes adjusted EBITDA as an operating performance measure in conjunction with GAAP measures such as net income. |
(6) | Adjusted EBITDA margin represents adjusted EBITDA divided by revenue. |
(7) | The Company records net tax expense (benefit) related to the income tax treatment of the fair value changes in the cash surrender value of its company owned life insurance. Since this change in fair value is unrelated to the Company’s operating performance, we excluded the impact on adjusted net income and adjusted diluted EPS. |
(8) | The consolidated effective tax rate is affected by the recording of excess tax benefits and tax deficiencies relating to equity awards vested and exercised during the period. As a result of the adoption of a new accounting pronouncement on January 1, 2017, the Company no longer records excess tax benefits and tax deficiencies to additional paid-in capital, but such excess tax benefits and tax deficiencies are now recognized in income tax expense. The magnitude of the impact of excess tax benefits and tax deficiencies generated in the future, which may be favorable or unfavorable, is dependent upon the Company’s future grants of share-based compensation, the Company’s future stock price on the date awards vest or exercise in relation to the fair value of the awards on the grant date or the exercise behavior of the Company’s stock appreciation rights holders. Since these excess tax benefits and tax deficiencies are largely unrelated to our income before taxes and are unrepresentative of our normal effective tax rate, we excluded their impact in the calculation of adjusted net income and adjusted diluted EPS. |
(9) | Adjusted net income represents GAAP net income excluding the impact of the (A) amortization of intangible assets, (B) acquisition, integration, and other costs, (C) extraordinary legal expenses, (D) changes in fair value of equity instruments, (E) write offs of deferred financing costs, (F) tax effect, if any, of the foregoing adjustments, (G) excess tax benefits and tax deficiencies relating to equity awards vested and exercised since January 1, 2017, and (H) net tax expense related to the income tax treatment of fair value changes in the cash surrender value of its company owned life insurance. Management included this non-GAAP measure to provide investors and prospective investors with an alternative method for assessing the Company’s operating results in a manner that is focused on its operating performance and to provide a more consistent basis for comparison between periods. However, investors and prospective investors should note that this non-GAAP measure involves judgment by management (in particular, judgment as to what is classified as a special item to be excluded in the calculation of adjusted net income). Although management believes the items in the calculation of adjusted net income are not indicative of the Company’s operating performance, these items do impact the statement of comprehensive income, and management therefore utilizes adjusted net income as an operating performance measure in conjunction with GAAP measures such as GAAP net income. |
(10) | Adjusted diluted EPS represents adjusted net income divided by diluted weighted average common shares outstanding. Management included this non-GAAP measure to provide investors and prospective investors with an alternative method for assessing the Company’s operating results in a manner that is focused on its operating performance and to provide a more consistent basis for comparison between periods. However, investors and prospective investors should note that this non-GAAP measure involves judgment by management (in particular, judgment as to what is classified as a special item to be excluded in the calculation of adjusted net income). Although management believes the items in the calculation of adjusted net income are not indicative of the Company’s operating performance, these items do impact the statement |
of comprehensive income, and management therefore utilizes adjusted diluted EPS as an operating performance measure in conjunction with GAAP measures such as GAAP diluted EPS.
(11) | Segment operating income represents net income plus interest expense (net of interest income) and other, income tax expense, depreciation and amortization, depreciation (included in cost of revenue), unallocated corporate overhead, acquisition, integration, and other costs, and share-based compensation. |
(12) | Average healthcare professionals on assignment represents the average number of nurse and allied healthcare professionals on assignment during the period presented. Excluding Advanced Medical, which was acquired during the second quarter of 2019, the average healthcare professionals on assignment was 10,087 and 9,900 for the three months ended March 31, 2020 and December 31, 2019, respectively. |
(13) | Days filled is calculated by dividing the locum tenens hours filled during the period by eight hours. |
(14) | Revenue per day filled represents revenue of the Company’s locum tenens business divided by days filled for the period presented. |
(15) | Leverage ratio represents the ratio of the consolidated funded indebtedness (as calculated per the Company’s credit agreement) at the end of the subject period to the consolidated adjusted EBITDA (as calculated per the Company’s credit agreement) for the twelve-month period ended at the end of the subject period. |
AMN Healthcare Segment Reporting Realignment (Unaudited) During the first quarter 2020 earnings release, AMN Healthcare Services, Inc. (NYSE: AMN) announced an update to our reportable segments. Effective January 1, 2020, our three reportable segments are (1) Nurse and Allied Solutions; (2) Physician and Leadership Solutions; and (3) Technology and Workforce Solutions. The nurse and allied solutions segment includes our travel nurse staffing, rapid response nurse staffing and labor disruption, allied staffing, local staffing, and revenue cycle solutions businesses. The physician and leadership solutions segment includes our locum tenens staffing, healthcare interim leadership staffing, executive search, and physician permanent placement businesses. The technology and workforce solutions segment includes remote video interpreting, vendor management systems, workforce optimization, recruitment process outsourcing, education, credentialing and flex pool management businesses. Non-GAAP Measures These slides contain certain non-GAAP financial information, which the Company provides as additional information, and not as an alternative, to the Company’s condensed consolidated financial statements presented in accordance with GAAP. These non-GAAP financial measures include (1) adjusted EBITDA and (2) adjusted EBITDA margin. The Company provides such non-GAAP financial measures because management believes that they are useful both to management and investors as a supplement, and not as a substitute, when evaluating the Company’s operating performance. Additionally, management believes that adjusted EBITDA and adjusted EBITDA margin serve as industry-wide financial measures. The non-GAAP measures provided in these slides are not in accordance with, or an alternative to, GAAP measures and may be different from non-GAAP measures, or may be calculated differently than other similarly titled non-GAAP measures, reported by other companies. They should not be used in isolation to evaluate the Company’s performance. Further detail about the use and limitations of the non-GAAP measures found in these slides may be found in the footnotes provided herein or on the Company’s website at http://amnhealthcare.investorroom.com/financialreports. Additionally, from time to time, additional information regarding non-GAAP financial measures, including pro forma measures, may be made available on the Company’s website. Presented below are the unaudited supplemental segment financial and operating data reflecting this realignment, including a Non-GAAP reconciliation table from net income to adjusted EBITDA, for the years ended December 31, 2019, 2018 and 2017. 1
AMN Healthcare Segment Reporting Realignment (Unaudited) Year Ended December 31, 2019 (dollars in thousands, except operating data) First Second Third Fourth Total Quarter Quarter Quarter Quarter Year Revenue Nurse and allied solutions $ 373,472 $ 367,994 $ 398,417 $ 422,705 $ 1,562,588 Physician and leadership solutions 137,077 142,449 143,842 139,394 562,762 Technology and workforce solutions 21,892 24,734 25,338 24,793 96,757 $ 532,441 $ 535,177 $ 567,597 $ 586,892 $ 2,222,107 Segment operating income (1) Nurse and allied solutions $ 53,556 $ 52,752 $ 52,533 $ 61,021 $ 219,862 Physician and leadership solutions 15,872 18,861 17,547 19,098 71,378 Technology and workforce solutions 10,383 11,336 11,426 10,754 43,899 $ 79,811 $ 82,949 $ 81,506 $ 90,873 $ 335,139 Unallocated corporate overhead 13,834 16,217 12,255 15,434 57,740 Adjusted EBITDA (2) $ 65,977 $ 66,732 $ 69,251 $ 75,439 $ 277,399 Adjusted EBITDA margin (3) 12.4% 12.5% 12.2% 12.9% 12.5% Gross Margin Nurse and allied solutions 28.5% 28.1% 28.5% 29.0% 28.5% Physician and leadership solutions 36.6% 37.2% 36.8% 37.2% 37.0% Technology and workforce solutions 92.6% 93.4% 93.0% 92.3% 92.8% Operating Data: Nurse and allied solutions Average healthcare professionals on assignment (4) 10,447 10,258 11,133 11,246 10,771 Physician and leadership solutions Days filled (5) 40,496 41,563 42,700 40,149 164,908 Revenue per day filled (6) $ 1,988 $ 1,975 $ 1,971 $ 1,941 $ 1,969 2
AMN Healthcare Segment Reporting Realignment (Unaudited) Year Ended December 31, 2019 (dollars in thousands) First Second Third Fourth Total Quarter Quarter Quarter Quarter Year Reconciliation of Non-GAAP Items: Net income $ 34,122 $ 28,869 $ 23,515 $ 27,482 $ 113,988 Income tax expense 5,257 10,222 8,394 10,627 34,500 Income before income taxes 39,379 39,091 31,909 38,109 148,488 Interest expense, net, and other 5,673 6,065 7,830 8,859 28,427 Income from operations 45,052 45,156 39,739 46,968 176,915 Depreciation and amortization 11,710 12,718 17,085 17,007 58,520 Share-based compensation (7) 5,186 3,702 2,825 4,528 16,241 Acquisition, integration, and other costs (8) 4,029 5,156 9,602 6,936 25,723 Adjusted EBITDA (2) $ 65,977 $ 66,732 $ 69,251 $ 75,439 $ 277,399 3
AMN Healthcare Segment Reporting Realignment (Unaudited) Year Ended December 31, 2018 (dollars in thousands, except operating data) First Second Third Fourth Total Quarter Quarter Quarter Quarter Year Revenue Nurse and allied solutions $ 346,542 $ 370,568 $ 346,268 $ 367,640 $ 1,431,018 Physician and leadership solutions 154,589 165,145 158,087 139,667 617,488 Technology and workforce solutions 21,358 22,395 22,487 21,328 87,568 $ 522,489 $ 558,108 $ 526,842 $ 528,635 $ 2,136,074 Segment operating income (1) Nurse and allied solutions $ 53,231 $ 50,314 $ 47,703 $ 50,618 $ 201,866 Physician and leadership solutions 19,743 25,232 23,003 18,099 86,077 Technology and workforce solutions 8,640 10,337 11,461 10,935 41,373 $ 81,614 $ 85,883 $ 82,167 $ 79,652 $ 329,316 Unallocated corporate overhead 15,095 15,823 14,739 13,281 58,938 Adjusted EBITDA (2) $ 66,519 $ 70,060 $ 67,428 $ 66,371 $ 270,378 Adjusted EBITDA margin (3) 12.7% 12.6% 12.8% 12.6% 12.7% Gross Margin Nurse and allied solutions 28.2% 27.1% 28.0% 27.8% 27.7% Physician and leadership solutions 32.9% 36.4% 36.3% 36.4% 35.5% Technology and workforce solutions 90.5% 91.4% 91.9% 91.7% 91.4% Operating Data: Nurse and allied solutions Average healthcare professionals on assignment (4) 9,813 10,012 9,896 10,303 10,006 Physician and leadership solutions Days filled (5) 52,794 55,225 50,069 41,000 199,089 Revenue per day filled (6) $ 1,953 $ 1,943 $ 2,019 $ 1,996 $ 1,976 4
AMN Healthcare Segment Reporting Realignment (Unaudited) Year Ended December 31, 2018 (dollars in thousands) First Second Third Fourth Total Quarter Quarter Quarter Quarter Year Reconciliation of Non-GAAP Items: Net income $ 42,681 $ 35,529 $ 27,918 $ 35,613 $ 141,741 Income tax expense 7,185 12,910 10,068 14,781 44,944 Income before income taxes 49,866 48,439 37,986 50,394 186,685 Interest expense, net, and other (9) 5,335 6,376 4,649 (217) 16,143 Income from operations 55,201 54,815 42,635 50,177 202,828 Depreciation and amortization 7,886 10,606 11,296 11,449 41,237 Share-based compensation (10) 2,864 3,281 1,809 2,861 10,815 Acquisition, integration, and other costs (11) 568 1,358 (452) 1,884 3,358 Legal settlement accrual increases (12) — — 12,140 — 12,140 Adjusted EBITDA (2) $ 66,519 $ 70,060 $ 67,428 $ 66,371 $ 270,378 5
AMN Healthcare Segment Reporting Realignment (Unaudited) Year Ended December 31, 2017 (dollars in thousands, except operating data) First Second Third Fourth Total Quarter Quarter Quarter Quarter Year Revenue Nurse and allied solutions $ 320,942 $ 308,306 $ 309,761 $ 329,107 $ 1,268,116 Physician and leadership solutions 153,933 159,334 162,024 158,749 634,040 Technology and workforce solutions 20,294 22,163 22,621 21,220 86,298 $ 495,169 $ 489,803 $ 494,406 $ 509,076 $ 1,988,454 Segment operating income (1) Nurse and allied solutions $ 47,891 $ 49,334 $ 41,325 $ 49,519 $ 188,069 Physician and leadership solutions 22,629 23,018 23,681 21,717 91,045 Technology and workforce solutions 7,536 9,911 10,129 8,678 36,254 $ 78,056 $ 82,263 $ 75,135 $ 79,914 $ 315,368 Unallocated corporate overhead 14,891 15,080 13,438 15,545 58,954 Adjusted EBITDA (2) $ 63,165 $ 67,183 $ 61,697 $ 64,369 $ 256,414 Adjusted EBITDA margin (3) 12.8% 13.7% 12.5% 12.6% 12.9% Gross Margin Nurse and allied solutions 28.0% 27.9% 27.3% 27.5% 27.7% Physician and leadership solutions 35.1% 34.1% 33.5% 32.9% 33.9% Technology and workforce solutions 89.2% 92.5% 91.7% 91.0% 91.2% Operating Data: Nurse and allied solutions Average healthcare professionals on assignment (4) 9,256 8,988 9,012 9,466 9,181 Physician and leadership solutions Days filled (5) 55,243 58,660 58,881 56,591 229,375 Revenue per day filled (6) $ 1,862 $ 1,845 $ 1,892 $ 1,911 $ 1,877 6
AMN Healthcare Segment Reporting Realignment (Unaudited) Year Ended December 31, 2017 (dollars in thousands) First Second Third Fourth Total Quarter Quarter Quarter Quarter Year Reconciliation of Non-GAAP Items: Net income $ 32,008 $ 31,255 $ 28,128 $ 41,167 $ 132,558 Income tax expense 14,897 20,197 17,863 7,248 60,205 Income before income taxes 46,905 51,452 45,991 48,415 192,763 Interest expense, net, and other 5,130 4,928 4,837 4,782 19,677 Income from operations 52,035 56,380 50,828 53,197 212,440 Depreciation and amortization 7,668 7,959 8,132 8,520 32,279 Share-based compensation 2,681 2,562 2,477 2,517 10,237 Acquisition, integration, and other costs 781 282 260 135 1,458 Adjusted EBITDA (2) $ 63,165 $ 67,183 $ 61,697 $ 64,369 $ 256,414 7
AMN Healthcare Segment Reporting Realignment (Unaudited) (1) Segment operating income represents net income plus interest expense (net of interest income) and other, income tax expense, depreciation and amortization, unallocated corporate overhead, acquisition, integration, and other costs, and share-based compensation. (2) Adjusted EBITDA represents net income plus interest expense (net of interest income) and other, income tax expense, depreciation and amortization, acquisition, integration, and other costs, extraordinary legal expenses, legal settlement accrual increases and share- based compensation. Management believes that adjusted EBITDA provides an effective measure of the Company’s results, as it excludes certain items that management believes are not indicative of the Company’s operating performance and is a measure used in the Company’s credit agreement and the indentures governing our 5.125% Senior Notes due 2024 and our 4.625% Senior Notes due 2027. Adjusted EBITDA is not intended to represent cash flows for the period, nor has it been presented as an alternative to income from operations or net income as an indicator of operating performance. Although management believes that some of the items excluded from adjusted EBITDA are not indicative of the Company’s operating performance, these items do impact the statement of comprehensive income, and management therefore utilizes adjusted EBITDA as an operating performance measure in conjunction with GAAP measures such as net income. (3) Adjusted EBITDA margin represents adjusted EBITDA divided by revenue. (4) Average healthcare professionals on assignment represents the average number of nurse and allied healthcare professionals on assignment and revenue cycle solutions professionals contracted by the Company during the period presented. Excluding Advanced Medical, which was acquired during the second quarter of 2019, the average healthcare professionals on assignment was 10,098 for the twelve months ended December 31, 2019. (5) Days filled is calculated by dividing the locum tenens hours filled during the period by eight hours. (6) Revenue per day filled represents revenue of the Company’s locum tenens business divided by days filled for the period presented. (7) Share-based compensation for the twelve months ended December 31, 2019 was impacted by two modifications during the first quarter and effective in 2019, a new vesting condition that resulted in accelerated expense recognition, and $1,209,000 of additional expense related to the performance equity awards during the fourth quarter of 2019. (8) Acquisition, integration, and other costs for the twelve months ended December 31, 2019 include net increases in the fair value of contingent consideration liabilities for recently acquired companies of $7,178,000 and extraordinary legal expenses of approximately $7,100,000. Beginning in 2019, we exclude the impact of extraordinary legal expenses from the calculation of adjusted EBITDA because we believe that these expenses are not indicative of the Company's operating performance. 8
AMN Healthcare Segment Reporting Realignment (Unaudited) Continued from page 8 (9) As a result of the adoption of a new accounting pronouncement on January 1, 2018, the Company now measures equity investments, except those accounted for using the equity method of accounting, at fair value with changes in fair value recognized through net income. Changes in fair value of equity investments recognized in interest expense, net, and other were $1,359,000 and $5,990,000 for the three months ended September 30, 2018 and December 31, 2018, respectively. (10) Share-based compensation for the three months ended September 30, 2018 was partially offset by a $1,610,000 reduction related to performance equity awards. (11) Acquisition, integration, and other costs of $874,000 for the three months ended September 30, 2018 were partially offset by a decrease in contingent consideration liabilities for recently acquired companies of $1,326,000. (12) During the third quarter of 2018, the Company recorded increases to its legal accruals established in connection with settlement agreements entered into during September and October 2018 in two class actions related to wage and hour claims, both of which are considered probable. For the three months ended September 30, 2018, the increases amounted to $12,140,000. Since the settlements are largely unrelated to the Company's operating performance, we excluded their impact in the calculation of adjusted EBITDA for the twelve months ended December 31, 2018. Amounts recorded in prior quarters in these two class actions and legal accruals related to other matters are immaterial and their impact was not excluded in the calculation of adjusted EBITDA in those prior quarters. 9